AI Article Synopsis
- Remimazolam is a new benzodiazepine that's effective for quick sedation and anesthesia, but it can cause rare, severe allergic reactions known as remimazolam-induced anaphylaxis (RIA).
- The study systematically reviewed cases of RIA to analyze symptoms, treatment methods, and patient demographics, focusing on factors like age, sex, and allergic responses to remimazolam.
- Key findings included that hypotension was the most common symptom among patients, and epinephrine was the main treatment used; guidelines for safe remimazolam use and the need for further research on risk factors were emphasized.
Article Abstract
: Remimazolam, a novel benzodiazepine, is used for procedural sedation and general anesthesia due to its rapid onset and short duration of action. However, remimazolam-induced anaphylaxis (RIA) is a rare but severe complication. This study aimed to analyze RIA characteristics, focusing on cardiovascular collapse, and provide guidelines for safe remimazolam use. : This study conducted a systematic review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Research articles retrieved from PubMed on 26 May 2023, using the keywords 'remimazolam AND anaphylaxis' were evaluated based on the inclusion criteria of being written in English and aligning with the World Allergy Organization criteria for anaphylaxis, while studies not meeting these criteria were excluded. All published articles up to the search date were included without any date restrictions. The review analyzed factors such as age, sex, type of anesthesia, remimazolam dose (bolus/continuous), allergic symptoms and sign, epinephrine use, serum tryptase levels, and skin prick tests. : Among eleven cases, the mean age was 55.6 ± 19.6 years, with 81.8% male. Hypotension (81.8%) was the most common symptom, followed by bradycardia (54.5%) and desaturation (36.4%). Two patients experienced cardiac arrest. Serum tryptase levels confirmed anaphylaxis in ten cases. Epinephrine was the primary treatment, with intravenous doses ranging from 0.1 mg to 0.3 mg. : Vigilance is crucial when administering remimazolam, adhering to recommended dosages, and promptly treating RIA with epinephrine. Further research is needed to understand the risk factors and refine the management strategies. Guidelines for safe remimazolam use are proposed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11205925 | PMC |
| http://dx.doi.org/10.3390/medicina60060971 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe Anaphylaxis From Remimazolam in a Mastocytosis Cancer Patient: A Case Report.
Cureus
September 2024
Department of Anesthesiology and Perioperative Medicine, MD Anderson Cancer Center, Houston, USA.
Remimazolam besylate is a novel, rapid-onset, ultra-short-acting benzodiazepine with an advantageous cardio-respiratory safety profile. To date, there have been few published reports of remimazolam-induced anaphylaxis, none of which are documented in patients with mast cell disease. We describe the case of a 77-year-old male with oncologic mastocytosis who developed anaphylaxis following remimazolam administration.
View Article and Find Full Text PDFRemimazolam-Induced Anaphylaxis and Cardiovascular Collapse: A Narrative Systematic Review of Eleven Cases.
Medicina (Kaunas)
June 2024
Department of Anesthesiology and Pain Medicine, Konkuk University Medical Center, Seoul 05030, Republic of Korea.
Article Synopsis
- Remimazolam is a new benzodiazepine that's effective for quick sedation and anesthesia, but it can cause rare, severe allergic reactions known as remimazolam-induced anaphylaxis (RIA).
- The study systematically reviewed cases of RIA to analyze symptoms, treatment methods, and patient demographics, focusing on factors like age, sex, and allergic responses to remimazolam.
- Key findings included that hypotension was the most common symptom among patients, and epinephrine was the main treatment used; guidelines for safe remimazolam use and the need for further research on risk factors were emphasized.
Laryngeal edema following remimazolam-induced anaphylaxis: a rare clinical manifestation.
BMC Anesthesiol
March 2023
Department of Anesthesiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Background: Remimazolam is an ultra-short-acting intravenous benzodiazepine, which has been used as sedative/anesthetic in procedural sedation and anesthesia. Although peri-operative anaphylaxis due to remimazolam has been reported recently, the spectrum of the allergic reactions is still not fully known.
Case Presentation: We describe a case of anaphylaxis following remimazolam administration in a male patient undergoing colonoscopy under procedural sedation.
Cardiac Arrest Following Remimazolam-Induced Anaphylaxis: A Case Report.
A A Pract
September 2022
From the Departments of Anesthesiology and Intensive Care.
Remimazolam is a recently approved benzodiazepine sedative. We report a case of a 72-year-old man who experienced a cardiac arrest due to severe anaphylaxis immediately after general anesthesia induction. Based on the results of skin tests, including those for dextran 40, an excipient in the remimazolam solution, and a review of drugs given during 3 anesthetics, remimazolam was identified as the probable causative agent.
View Article and Find Full Text PDFAnaphylactic reactions during the induction of general anaesthesia are rare. Anaesthetists should determine the pathogenesis of anaphylaxis in order to establish appropriate treatment and prevent recurrence. Very little clinical information has been published to date about anaphylaxis induced by the recently launched drug remimazolam.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!